Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction

European Journal of Heart Failure

Volumn 17, Issue 5, 2015, Pages 510-517

  Voors, Adriaan A ^a   Gori, Mauro ^b   Liu, Licette C Y ^a   Claggett, Brian ^b   Zile, Michael R ^c   Pieske, Burkert ^d   McMurray, John J V ^e   Packer, Milton ^f   Shi, Victor ^g   Lefkowitz, Martin P ^g   Solomon, Scott D ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Albumin excretion; Angiotensin receptor neprilysin inhibitor; LCZ696; Renal function

Indexed keywords

CREATININE; CYSTATIN C; PLACEBO; SACUBITRIL PLUS VALSARTAN; VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; MEMBRANE METALLOENDOPEPTIDASE; TETRAZOLE DERIVATIVE;

AGED; ARTICLE; CARDIAC PATIENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFECT; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; INCIDENCE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT DURATION; URINARY ALBUMIN TO CREATININE RATIO; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; HEART FAILURE; HEART STROKE VOLUME; KIDNEY; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMINOBUTYRATES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN RECEPTOR ANTAGONISTS; CREATININE; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; KIDNEY; MALE; MIDDLE AGED; NEPRILYSIN; STROKE VOLUME; TETRAZOLES; VALSARTAN;

EID: 84928609455     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.232     Document Type: Article

References (67)

1. Blankstein R, Bakris GL,. Changes in kidney function following heart failure treatment: focus on renin-angiotensin system blockade. Heart Fail Clin 2008; 4: 425-438.
2. Voors AA, Dorhout B, van der Meer P,. The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure. Expert Opin Investig Drugs 2013; 22: 1041-1047.
3. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004.
4. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ, Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012; 380: 1387-1395.
5. Metra M, Cotter G, Gheorghiade M, Dei Cas L, Voors AA,. The role of the kidney in heart failure. Eur Heart J 2012; 33: 2135-2142.
6. Richards AM, Wittert GA, Crozier IG, Espiner EA, Yandle TG, Ikram H, Frampton C,. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens 1993; 11: 407-416.
7. Regamey F, Maillard M, Nussberger J, Brunner HR, Burnier M,. Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men. Hypertension 2002; 40: 266-272.
8. Chee KH, Amudha K, Hussain NA, Haizal HK, Choy AM, Lang CC,. Combination of drugs acting on the natriuretic system and the renin-angiotensin system in heart failure. J Renin Angiotensin Aldosterone Syst 2003; 4: 140-148.
9. Nagatomo Y, Kitamura K, Kangawa K, Fujimoto Y, Eto T,. Proadrenomedullin N-terminal 20 peptide is rapidly cleaved by neutral endopeptidase. Biochem Biophys Res Commun 1996; 223: 539-543.
10. Kaplan AP, Ghebrehiwet B,. The plasma bradykinin-forming pathways and its interrelationships with complement. Mol Immunol 2010; 47: 2161-2169.
11. Dunn BR, Ichikawa I, Pfeffer JM, Troy JL, Brenner BM,. Renal and systemic hemodynamic effects of synthetic atrial natriuretic peptide in the anesthetized rat. Circ Res 1986; 59: 237-246.
12. Mejia R, Sands JM, Stephenson JL, Knepper MA,. Renal actions of atrial natriuretic factor: a mathematical modeling study. Am J Physiol 1989; 257: F1146-F1157.
13. Pham I, Sediame S, Maistre G, Roudot-Thoraval F, Chabrier PE, Carayon A, Adnot S,. Renal and vascular effects of C-type and atrial natriuretic peptides in humans. Am J Physiol 1997; 273: R1457-R1464.
14. Tabrizchi R,. Dual ACE and neutral endopeptidase inhibitors: novel therapy for patients with cardiovascular disorders. Drugs 2003; 63: 2185-2202.
15. Jose P, Skali H, Anavekar N, Tomson C, Krumholz HM, Rouleau JL, Moye L, Pfeffer MA, Solomon SD,. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J Am Soc Nephrol 2006; 17: 2886-2891.
16. Vardeny O, Wu DH, Desai A, Rossignol P, Zannad F, Pitt B, Solomon SD, RALES Investigators. Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol 2012; 60: 2082-2089.
17. Damman K, Perez AC, Anand IS, Komajda M, McKelvie RS, Zile MR, Massie B, Carson PE, McMurray JJ,. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. J Am Coll Cardiol 2014; 64: 1106-1113.
18. Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, Maahs S, Ksander G, Rigel DF, Jeng AY, Lin TH, Zheng W, Dole WP,. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 2010; 50: 401-414.
19. Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP,. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010; 375: 1255-1266.
20. Smilde TD, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL,. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 2006; 114: 1572-1580.
21. Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL,. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 2014; 35: 455-469.
22. Brown EG, Wood L, Wood S,. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999; 20: 109-117.
23. Brown EG,. Methods and pitfalls in searching drug safety databases utilising the Medical Dictionary for Regulatory Activities (MedDRA). Drug Saf 2003; 26: 145-158.
24. Palmer BF,. Renal dysfunction complicating the treatment of hypertension. N Engl J Med 2002; 347: 1256-1261.
25. Damman K, Voors AA, Navis G, van Veldhuisen DJ, Hillege HL,. The cardiorenal syndrome in heart failure. Prog Cardiovasc Dis 2011; 54: 144-153.
26. Richards M, Espiner E, Frampton C, Ikram H, Yandle T, Sopwith M, Cussans N,. Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects. Hypertension 1990; 16: 269-276.
27. Lipkin GW, Dawnay AB, Harwood SM, Cattell WR, Raine AE,. Enhanced natriuretic response to neutral endopeptidase inhibition in patients with moderate chronic renal failure. Kidney Int 1997; 52: 792-801.
28. Chen HH, Schirger JA, Chau WL, Jougasaki M, Lisy O, Redfield MM, Barclay PT, Burnett JC Jr., Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure. Circulation 1999; 100: 2443-2448.
29. Levin ER, Gardner DG, Samson WK,. Natriuretic peptides. N Engl J Med 1998; 339: 321-328.
30. Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC Jr., Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J 2013; 34:886-893c.
31. Lainchbury JG, Nicholls MG, Espiner EA, Ikram H, Yandle TG, Richards AM,. Regional plasma levels of cardiac peptides and their response to acute neutral endopeptidase inhibition in man. Clin Sci (Lond) 1998; 95: 547-555.
32. Marin-Grez M, Fleming JT, Steinhausen M,. Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney. Nature 1986; 324: 473-476.
33. Lanese DM, Yuan BH, Falk SA, Conger JD,. Effects of atriopeptin III on isolated rat afferent and efferent arterioles. Am J Physiol 1991; 261: F1102-F1109.
34. Ohishi K, Hishida A, Honda N,. Direct vasodilatory action of atrial natriuretic factor on canine glomerular afferent arterioles. Am J Physiol 1988; 255: F415-F420.
35. Loutzenhiser R, Hayashi K, Epstein M,. Atrial natriuretic peptide reverses afferent arteriolar vasoconstriction and potentiates efferent arteriolar vasoconstriction in the isolated perfused rat kidney. J Pharmacol Exp Ther 1988; 246: 522-528.
36. Kimura K, Hirata Y, Nanba S, Tojo A, Matsuoka H, Sugimoto T,. Effects of atrial natriuretic peptide on renal arterioles: morphometric analysis using microvascular casts. Am J Physiol 1990; 259: F936-F944.
37. Testani JM, Kimmel SE, Dries DL, Coca SG,. Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail 2011; 4: 685-691.
38. Vardeny O, Wu DH, Desai A, Rossignol P, Zannad F, Pitt B, Solomon SD, RALES Investigators. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol 2012; 60: 2082-2089.
39. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A, I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456-2467.
40. Jose P, Skali H, Anavekar N, Tomson C, Krumholz HM, Rouleau JL, Moye L, Pfeffer MA, Solomon SD,. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J Am Soc Nephrol 2006; 17: 2886-2891.
41. Dharnidharka VR, Kwon C, Stevens G,. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40: 221-226.
42. Damman K, van der Harst P, Smilde TD, Voors AA, Navis G, van Veldhuisen DJ, Hillege HL,. Use of cystatin C levels in estimating renal function and prognosis in patients with chronic systolic heart failure. Heart 2012; 98: 319-324.
43. Laterza OF, Price CP, Scott MG,. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 2002; 48: 699-707.
44. Coll E, Botey A, Alvarez L, Poch E, Quinto L, Saurina A, Vera M, Piera C, Darnell A,. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000; 36: 29-34.
45. Hojs R, Bevc S, Ekart R, Gorenjak M, Puklavec L,. Serum cystatin C-based equation compared with serum creatinine-based equations for estimation of glomerular filtration rate in patients with chronic kidney disease. Clin Nephrol 2008; 70: 10-17.
46. Nosaka K, Nakamura K, Kusano K, Toh N, Tada T, Miyoshi T, Doi M, Kohno K, Morita H, Ito H,. Serum cystatin C as a biomarker of cardiac diastolic dysfunction in patients with cardiac disease and preserved ejection fraction. Congest Heart Fail 2013; 19: E35-E39.
47. Kampoli AM, Tousoulis D, Papageorgiou N, Pallatza Z, Vogiatzi G, Briasoulis A, Androulakis E, Toutouzas C, Stougianos P, Tentolouris C, Stefanadis C,. Clinical utility of biomarkers in premature atherosclerosis. Curr Med Chem 2012; 19: 2521-2533.
48. Salgado JV, Souza FL, Salgado BJ,. How to understand the association between cystatin C levels and cardiovascular disease: imbalance, counterbalance, or consequence? J Cardiol 2013; 62: 331-335.
49. Li X, Zhu H, Li P, Xin Q, Liu J, Zhang W, Xing YH, Xue H,. Serum cystatin C concentration as an independent marker for hypertensive left ventricular hypertrophy. J Geriatr Cardiol 2013; 10: 286-290.
50. Prats M, Font R, Bardaji A, Gutierrez C, Lalana M, Vilanova A, Martinez-Vea A,. Cystatin C and cardiac hypertrophy in primary hypertension. Blood Press 2010; 19: 20-25.
51. Watanabe S, Okura T, Liu J, Miyoshi K, Fukuoka T, Hiwada K, Higaki J,. Serum cystatin C level is a marker of end-organ damage in patients with essential hypertension. Hypertens Res 2003; 26: 895-899.
52. Ishi M, Hirata Y, Sugimoto T, Matsuoka H, Kimura K, Ishimitsu T, Fukui K, Sugimoto T, Kurosawa Y, Kiyose H,. Effect of alpha-human atrial natriuretic peptide on proteinuria in patients with primary glomerular diseases. Clin Sci (Lond) 1989; 77: 643-650.
53. Moore KB, McKenna K, Osman M, Tormey WP, McDonald D, Thompson CJ,. Atrial natriuretic peptide increases urinary albumin excretion in people with normoalbuminuric type-2 diabetes. Ir J Med Sci 2007; 176: 67-73.
54. Vervoort G, Wetzels JF, Lutterman JA, Bravenboer B, Berden JH, Smits P,. Atrial natriuretic peptide-induced microalbuminuria is associated with endothelial dysfunction in noncomplicated type 1 diabetes patients. Am J Kidney Dis 2002; 40: 9-15.
55. Prasad N, Clarkson PB, MacDonald TM, Ryan M, Struthers AD, Thompson CJ,. Atrial natriuretic peptide increases urinary albumin excretion in men with type 1 diabetes mellitus and established microalbuminuria. Diabet Med 1998; 15: 678-682.
56. Vervoort G, Hertenberg F, Wetzels JF, Smits P,. Influence of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor antagonism on renal sodium and water handling and albuminuria during infusion of atrial natriuretic factor into healthy volunteers. J Hypertens 1998; 16: 245-250.
57. McMurray J, Seidelin PH, Howey JE, Balfour DJ, Struthers AD,. The effect of atrial natriuretic factor on urinary albumin and beta 2-microglobulin excretion in man. J Hypertens 1988; 6: 783-786.
58. Lofton CE, Newman WH, Currie MG,. Atrial natriuretic peptide regulation of endothelial permeability is mediated by cGMP. Biochem Biophys Res Commun 1990; 172: 793-799.
59. Battle T, Michel JB, Corman B,. Effect of atrial natriuretic factor on the water permeability of endothelial cells. Biochem Biophys Res Commun 1992; 185: 386-391.
60. Huxley VH, Tucker VL, Verburg KM, Freeman RH,. Increased capillary hydraulic conductivity induced by atrial natriuretic peptide. Circ Res 1987; 60: 304-307.
61. Renkin EM, Tucker VL,. Atrial natriuretic peptide as a regulator of transvacular fluid balance. Physiology 1996; 11: 138-143.
62. Axelsson J, Rippe A, Rippe B,. Transient and sustained increases in glomerular permeability following ANP infusion in rats. Am J Physiol Renal Physiol 2011; 300: F24-F30.
63. Segawa K, Minami K, Jimi N, Nakashima Y, Shigematsu A,. C-type natriuretic peptide inhibits rat mesangial cell proliferation by a phosphorylation-dependent mechanism. Naunyn Schmiedebergs Arch Pharmacol 1998; 357: 70-76.
64. Canaan-Kuhl S, Ostendorf T, Zander K, Koch KM, Floege J,. C-type natriuretic peptide inhibits mesangial cell proliferation and matrix accumulation in vivo. Kidney Int 1998; 53: 1143-1151.
65. Kohno M, Yasunari K, Maeda K, Kano H, Minami M, Hanehira T, Yoshikawa J,. Effects of cardiac natriuretic peptides on oxidized low-density lipoprotein- and lysophosphatidylcholine-induced human mesangial cell migration. Hypertension 2000; 35: 971-977.
66. Osawa H, Yamabe H, Kaizuka M, Tamura N, Tsunoda S, Baba Y, Shirato K, Tateyama F, Okumura K,. C-type natriuretic peptide inhibits proliferation and monocyte chemoattractant protein-1 secretion in cultured human mesangial cells. Nephron 2000; 86: 467-472.
67. Appel RG, Wang J, Simonson MS, Dunn MJ,. A mechanism by which atrial natriuretic factor mediates its glomerular actions. Am J Physiol 1986; 251: F1036-F1042.